Crafton is developing a focused pipeline of mRNA programs designed to validate and apply its high-purity mRNA platform. Our strategy is to prioritize indications where mRNA quality, dose efficiency, tolerability, and manufacturing speed may provide meaningful clinical or development advantages.
In parallel, Crafton pursues platform collaborations to evaluate PureCap across external mRNA payloads and disease areas.